NCT01208779已完成不适用
An Epidemiological, Non-interventional Study to Evaluate Patient Compliance in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 90
- 试验地点
- 1
- 主要终点
- Evaluate compliance rate, as assessed by investigator, after 12 months from baseline.
研究概览
简要总结
This observational study in estrogen receptor positive early breast cancer patients is aimed to evaluate the patients' compliance to aromatase inhibitor (AI) therapy and to collect country-specific data in estrogen receptor positive early breast cancer patients including data on demography, disease characteristics and disease management.
研究设计
- 研究类型
- Observational
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Postmenopausal females with estrogen receptor positive breast cancer that are currently treated with aromatase inhibitor (AI) medication
- •Provision of subject informed consent
排除标准
- •If participating in any clinical trial, the subject cannot take part in this study.
结局指标
主要结局
Evaluate compliance rate, as assessed by investigator, after 12 months from baseline.
时间窗: 12 months
次要结局
- Evaluate compliance rate, assessed by investigator, after 6 months of follow up(12 months)
- Evaluate the extent of patient educational activities as assessed by patient (using patient questionnaire) after 6 and 12 months(12 months)
- Evaluate patient compliance as assessed by the patient (using patient questionnaire) after 6 and 12 months(12 months)
- Collect epidemiology data; Demographic data: age, height, weight, lifestyle, menarche, childbirth, lactation, menopausal status(12 months)
- Primary disease (breast cancer) characteristics: receptor status, disease stage(12 months)
- Disease management data: treatment/treatment changes(12 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Evaluation of a Pilot Breast Cancer Survivorship Care Plan in New ZealandBreast cancer survivorship care planCancer - BreastBreast cancerACTRN12612001175864Regional Cancer Treatment Service, MidCentral Health DHB30
已完成
2 期
Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast CancerHER2-negative Breast CancerNode-negative Breast CancerBreast CarcinomaBreast CancerNCT05150652Irada Ibrahim-zada8
进行中（未招募）
2 期
Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast CancerBreast CancerNCT03573648Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins33
已完成
不适用
Observational Study to Evaluate Mechanisms of Aromatase Inhibitor Associated Musculoskeletal SymptomsArthralgiaBreast CancerNCT02118636Lynn Henry75
已完成
2 期
Palbociclib and FES PETBreast CancerNCT02806050University Medical Center Groningen30